Total Payments
$871,726
2024 Payments
$204,638
Companies
20
Transactions
1,260
Medicare Patients
10,880
Medicare Billing
$1.9M
Payment Breakdown by Category
Other$687,224 (78.8%)
Travel$97,958 (11.2%)
Consulting$56,214 (6.4%)
Food & Beverage$30,162 (3.5%)
Education$168.44 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $681,825 | 323 | 78.2% |
| Travel and Lodging | $97,958 | 340 | 11.2% |
| Consulting Fee | $56,214 | 42 | 6.4% |
| Food and Beverage | $30,162 | 546 | 3.5% |
| Honoraria | $5,200 | 3 | 0.6% |
| Entertainment | $198.90 | 1 | 0.0% |
| Education | $168.44 | 5 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $317,028 | 412 | $0 (2024) |
| GlaxoSmithKline, LLC. | $257,082 | 309 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $189,087 | 314 | $0 (2021) |
| Mylan Specialty L.P. | $43,227 | 99 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $26,080 | 56 | $0 (2024) |
| PORTOLA PHARMACEUTICALS, INC. | $14,760 | 18 | $0 (2019) |
| AstraZeneca UK Limited | $9,926 | 8 | $0 (2022) |
| Regeneron Healthcare Solutions, Inc. | $8,641 | 10 | $0 (2024) |
| Edwards Lifesciences Corporation | $1,600 | 2 | $0 (2021) |
| La Jolla Pharmaceutical Company | $1,345 | 4 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $204,638 | 241 | AstraZeneca Pharmaceuticals LP ($107,072) |
| 2023 | $233,912 | 275 | GlaxoSmithKline, LLC. ($116,786) |
| 2022 | $90,035 | 114 | AstraZeneca Pharmaceuticals LP ($41,875) |
| 2021 | $66,749 | 98 | AstraZeneca Pharmaceuticals LP ($33,785) |
| 2020 | $30,653 | 59 | GlaxoSmithKline, LLC. ($15,044) |
| 2019 | $87,670 | 172 | Sunovion Pharmaceuticals Inc. ($68,746) |
| 2018 | $97,148 | 202 | Sunovion Pharmaceuticals Inc. ($79,111) |
| 2017 | $60,921 | 99 | Sunovion Pharmaceuticals Inc. ($34,999) |
All Payment Transactions
1,260 individual payment records from CMS Open Payments — Page 1 of 51
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: RESPIRATORY | ||||||
| 12/11/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: RESPIRATORY | ||||||
| 12/11/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: RESPIRATORY | ||||||
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Respiratory | ||||||
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,850.00 | General |
| Category: Respiratory | ||||||
| 12/05/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Travel and Lodging | Cash or cash equivalent | $113.52 | General |
| Category: RESPIRATORY | ||||||
| 12/05/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $31.80 | General |
| Category: Respiratory | ||||||
| 12/05/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $28.98 | General |
| Category: RESPIRATORY | ||||||
| 12/05/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | Cash or cash equivalent | $12.78 | General |
| Category: RESPIRATORY | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $803.68 | General |
| Category: Respiratory | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $100.21 | General |
| Category: Respiratory | ||||||
| 12/03/2024 | Harmony Biosciences Llc | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $8.65 | General |
| Category: Narcoplepsy | ||||||
| 11/19/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: RESPIRATORY | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,850.00 | General |
| Category: Respiratory | ||||||
| 11/14/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $118.81 | General |
| Category: Respiratory | ||||||
| 11/14/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Travel and Lodging | In-kind items and services | $14.05 | General |
| Category: Respiratory | ||||||
| 11/14/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $8.10 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 11/13/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Travel and Lodging | In-kind items and services | $1,229.52 | General |
| Category: RESPIRATORY | ||||||
| 11/13/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $110.19 | General |
| Category: RESPIRATORY | ||||||
| 11/13/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $28.19 | General |
| Category: Respiratory | ||||||
| 11/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $6.78 | General |
| Category: RESPIRATORY | ||||||
| 11/06/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: RESPIRATORY | ||||||
| 11/01/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,700.00 | General |
| Category: Respiratory | ||||||
| 11/01/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,700.00 | General |
| Category: Respiratory | ||||||
| 11/01/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 3,298 | 6,282 | $988,052 | $527,793 |
| 2022 | 16 | 2,800 | 5,386 | $807,024 | $431,884 |
| 2021 | 19 | 2,477 | 5,051 | $841,004 | $458,069 |
| 2020 | 20 | 2,305 | 5,471 | $985,683 | $501,025 |
Total Patients
10,880
Total Services
22,190
Medicare Billing
$1.9M
Procedure Codes
74
All Medicare Procedures & Services
74 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 245 | 1,537 | $265,133 | $153,017 | 57.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 632 | 1,148 | $175,587 | $118,253 | 67.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 74 | 369 | $152,022 | $64,472 | 42.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 243 | 279 | $96,255 | $39,969 | 41.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 303 | 392 | $39,220 | $27,763 | 70.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 176 | 176 | $52,800 | $21,134 | 40.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 143 | 319 | $37,419 | $20,800 | 55.6% |
| 94664 | Evaluation of use of breathing device | Office | 2023 | 481 | 971 | $38,957 | $14,853 | 38.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 88 | 93 | $21,230 | $13,836 | 65.2% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 252 | 280 | $21,000 | $12,607 | 60.0% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 252 | 280 | $18,200 | $11,481 | 63.1% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 32 | 33 | $11,550 | $7,875 | 68.2% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 251 | 278 | $18,070 | $7,797 | 43.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 30 | 30 | $10,230 | $5,458 | 53.3% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 17 | 18 | $8,100 | $3,148 | 38.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 28 | 28 | $5,936 | $2,614 | 44.0% |
| 31645 | Aspiration of initial secretion of lung airway using an endoscope | Facility | 2023 | 17 | 17 | $5,433 | $1,696 | 31.2% |
| 31646 | Aspiration of subsequent secretions of lung airway using an endoscope during same hospital stay | Facility | 2023 | 17 | 17 | $5,386 | $990.25 | 18.4% |
| 31624 | Irrigation and suction of lung airways to obtain cells using an endoscope | Facility | 2023 | 17 | 17 | $5,525 | $29.12 | 0.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 634 | 1,199 | $183,387 | $120,928 | 65.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 188 | 1,138 | $196,305 | $97,908 | 49.9% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 60 | 296 | $119,777 | $53,949 | 45.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 170 | 210 | $72,450 | $33,537 | 46.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 149 | 149 | $44,700 | $20,026 | 44.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 104 | 272 | $31,906 | $16,289 | 51.1% |
About Dr. Hoang Le, M.D
Dr. Hoang Le, M.D is a Pulmonary Disease healthcare provider based in Fountain Valley, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1104886241.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hoang Le, M.D has received a total of $871,726 in payments from pharmaceutical and medical device companies, with $204,638 received in 2024. These payments were reported across 1,260 transactions from 20 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($681,825).
As a Medicare-enrolled provider, Le has provided services to 10,880 Medicare beneficiaries, totaling 22,190 services with total Medicare billing of $1.9M. Data is available for 4 years (2020–2023), covering 74 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Specialist
- Location Fountain Valley, CA
- Active Since 03/24/2006
- Last Updated 08/16/2019
- Taxonomy Code 207RP1001X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1104886241
Products in Payments
- BREZTRI (Drug) $255,608
- AREXVY (Drug) $148,911
- LONHALA MAGNAIR (Drug) $98,287
- TRELEGY ELLIPTA (Drug) $66,599
- UTIBRON (Drug) $62,652
- YUPELRI (Drug) $25,710
- AIRSUPRA (Drug) $25,425
- Yupelri (Drug) $17,517
- BEVESPI AEROSPHERE (Drug) $15,817
- SEEBRI (Drug) $13,766
- SPIRIVA RESPIMAT (Drug) $12,612
- BEVYXXA (Drug) $10,400
- DUPIXENT (Biological) $8,797
- BREZTRI AEROSPHERE (Drug) $8,552
- LATUDA (Drug) $5,002
- BEVYXXA (Biological) $4,246
- GIAPREZA (Drug) $1,345
- Monarch Platform (Device) $1,194
- B Flex (Device) $500.00
- OFEV (Drug) $454.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Fountain Valley
Dr. Viney Soni, M.d, M.D
Pulmonary Disease — Payments: $16,283
Pulmonary Disease $16,283
Malaygiri Aparnath, Md, MD
Pulmonary Disease — Payments: $14,395
Pulmonary Disease $14,395
Thomas Asciuto
Pulmonary Disease — Payments: $8,786
Pulmonary Disease $8,786
Dr. John Saito, Md, MD
Pulmonary Disease — Payments: $8,478
Pulmonary Disease $8,478
Dr. Abhishek Bhardwaj, M.d, M.D
Pulmonary Disease — Payments: $4,044
Pulmonary Disease $4,044
Dr. Prakash Bondade, M.d, M.D
Pulmonary Disease — Payments: $3,893
Pulmonary Disease $3,893